Zaltrap Articles

Regeneron posts strong growth for 2012, beating analysts' estimates

15 February 2013

Sanofi's Zaltrap gets EU approval for metastatic colorectal cancer

6 February 2013

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19 November 2012

Sanofi halves US price of Zaltrap, responding to criticism from oncologists

12 November 2012

Positive Ph III VELOUR results with Sanofi's Zaltrap

10 October 2012

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

7 October 2012

Zaltrap gains US approval for metastatic colorectal cancer

6 August 2012

Sanofi and Regeneron mCRC drug Zaltrap misses goals but gets FDA priority

10 April 2012

Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival

7 June 2011

Regeneron/Sanofi colorectal cancer drug Zaltrap will see peak-year sales of up to $250 million

13 May 2011

Sanofi-Aventis and Regeneron’s Zaltrap improves OS in Ph III colon cancer study

28 April 2011

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end